Closing 18-month outcomes of the EVAPORATE trial point out icosapent ethyl (Vascepa) offers even elevated slowing of coronary plaque development when added to statins for…
Closing 18-month outcomes of the EVAPORATE trial point out icosapent ethyl (Vascepa) offers even elevated slowing of coronary plaque development when added to statins for…